Mesa Laboratories (NASDAQ:MLAB) Share Price Crosses Below 200-Day Moving Average of $100.91

Mesa Laboratories, Inc. (NASDAQ:MLAB) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $100.91 and traded as low as $99.27. Mesa Laboratories shares last traded at $99.88, with a volume of 25,382 shares.

Analyst Ratings Changes

Separately, Evercore ISI upgraded Mesa Laboratories from an “in-line” rating to an “outperform” rating and increased their price target for the stock from $100.00 to $125.00 in a report on Thursday, January 4th.

Mesa Laboratories Trading Up 4.8 %

The company has a 50 day moving average of $101.03 and a 200-day moving average of $100.81. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.86 and a current ratio of 2.68. The stock has a market cap of $578.08 million, a price-to-earnings ratio of 630.92 and a beta of 0.83.

Mesa Laboratories (NASDAQ:MLAB) last posted its quarterly earnings results on Monday, February 5th. The medical instruments supplier reported $1.46 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.47 by ($0.01). The company had revenue of $53.47 million during the quarter, compared to analyst estimates of $54.90 million. Mesa Laboratories had a net margin of 0.45% and a return on equity of 7.41%. On average, research analysts anticipate that Mesa Laboratories, Inc. will post 6.15 earnings per share for the current year.

Mesa Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, March 15th. Stockholders of record on Thursday, February 29th were given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 0.60%. The ex-dividend date of this dividend was Wednesday, February 28th. Mesa Laboratories’s dividend payout ratio (DPR) is presently 376.49%.

Institutional Investors Weigh In On Mesa Laboratories

Several hedge funds and other institutional investors have recently made changes to their positions in MLAB. Vanguard Group Inc. grew its stake in Mesa Laboratories by 2.0% during the 4th quarter. Vanguard Group Inc. now owns 370,278 shares of the medical instruments supplier’s stock worth $38,794,000 after buying an additional 7,274 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Mesa Laboratories by 5.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,698 shares of the medical instruments supplier’s stock valued at $283,000 after buying an additional 136 shares during the period. Barclays PLC lifted its holdings in shares of Mesa Laboratories by 359.8% in the 4th quarter. Barclays PLC now owns 11,664 shares of the medical instruments supplier’s stock valued at $1,222,000 after buying an additional 9,127 shares during the period. Nuveen Asset Management LLC raised its holdings in Mesa Laboratories by 0.9% during the fourth quarter. Nuveen Asset Management LLC now owns 13,106 shares of the medical instruments supplier’s stock worth $1,373,000 after purchasing an additional 120 shares during the last quarter. Finally, Public Sector Pension Investment Board raised its holdings in Mesa Laboratories by 68.2% during the fourth quarter. Public Sector Pension Investment Board now owns 10,631 shares of the medical instruments supplier’s stock worth $1,114,000 after purchasing an additional 4,309 shares during the last quarter. Institutional investors and hedge funds own 90.60% of the company’s stock.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc develops, manufactures, and sells life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. It operates in four segments: Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions.